Programme overview
Download the Programme and Abstract Book
The Programme below is based on IST time (GMT +5.30)
The Programme below is based on IST time (GMT +5.30)
The Programme below is based on IST time (GMT +5.30)
The Programme below is based on IST time (GMT +5.30)
| Timing (IST / GMT +5.30) |
PRE-CONGRESS: 16 Sept 2022, Friday | |
|---|---|---|
| ASAP Symposium: Updates on Pneumococcal Vaccines Development Chair: Lulu C. Bravo (Philippines) Zulkifli Ismail (Malaysia) |
HPV Workshop Chair: Kirthini Muralidharan (United States of America) |
|
| 0800 - 1030 hrs | Egemen Ozbilgili (Pfizer)Olakunle Oladehin (GSK)Jin Oh Kim (MSD)Nitin Shah | Daniel Chulwoo Rhee (United States of America)Didik Setiawan (Indonesia)Kurnia Eka Wijayanti (Indonesia) |
| VACCINOLOGY MASTERCLASS : ASVAC 2022 | ||
| 1030 - 1040 hrs | Welcome AddressDaniel Goh (Singapore) | |
| 1040 - 1100 hrs | History & Impact of VaccinationMathu Santhosham (United States of America) | |
| 1100 - 1220 hrs | Basic Vaccine Immunology | |
| 1100 - 1120 hrs | How & Why Vaccines Work: Basics of Immune Responses and Mechanisms of VaccinesPhilippe Buchy (Singapore) | |
| 1120 - 1140 hrs | Fundamentals of Vaccine Clinical DevelopmentAlberta Di Pasquale (Singapore) | |
| 1140 - 1200 hrs | Importance of Disease Surveillance in Vaccination StrategiesPhilippe Buchy (Singapore) | |
| 1200 - 1220 hrs | Concept of Cross-Protection and Herd ImmunityJin Oh Kim (South Korea) | |
| 1220 - 1230 hrs | Break | |
| 1230 - 1300 hrs | Communications - Addressing Vaccine HesitancyZulkifli Ismail (Malaysia) | |
| 1300 - 1500 hrs | Vaccination through the Ages - Vaccines in Each Stage of Life | |
| 1300 - 1330 hrs | Vaccination in InfantsElizabeth Gallardo (Philippines) | |
| 1330 - 1400 hrs | Vaccination in AdolescentsPramod Jog (India) | |
| 1400 - 1430 hrs | Vaccination in PregnancySybil Bravo (Philippines) | |
| 1430 - 1500 hrs | Vaccination in ElderlyJean-Pierre Michel (Switzerland) | |
| 1500 - 1530 hrs | Clinical ApplicationH.T. Wickramasinghe (Sri Lanka) Rajiva de Silva (Sri Lanka) |
|
| 1530 - 1550 hrs | Vaccines: What Lies in the Future?Jerome Kim (South Korea) | |
| 1550 - 1600 hrs | Concluding RemarksDaniel Goh (Singapore) | |
| 1600 hrs | End of Pre-Congress Programme | |
The Programme below is based on IST time (GMT +5.30)
| Timing (IST / GMT +5.30) |
DAY 1: 17 Sept 2022, Saturday | |
|---|---|---|
| Stream 1 | Stream 2 | |
| 0830 - 0840 hrs | Welcome AddressLulu C. Bravo (Philippines) | |
| 0840 - 0850 hrs | Introduction to ASVAC 2022H.T. Wickramasinghe (Sri Lanka) | |
| 0850 - 0900 hrs | Opening MessageKeheliya Rambukkwella (Hon. Minister of Health, Sri Lanka) | |
| 0900 - 0930 hrs | Plenary Lecture 1 Chair: Lulu C. Bravo (Philippines) |
|
| Equity and COVIDKim Mulholland (Australia) | ||
| 0930 - 1045 hrs | Symposium 1: Vaccines through the AgesPartners: International Federation of Aging |
Symposium 2: Respiratory VaccinesPartners: Asia Pacific Alliance for the Control of Influenza (APACI) |
| Chair: Susie Perera (Sri Lanka) | Chair: Neelika Malavige (Sri Lanka) | |
| 0930 – 0950 hrs | Implementing Life Course Immunisation Schedules: What Needs to be DoneJane Barret (Canada) | Flu Vaccine UpdatesPushpa Ranjan Wijesinghe (India) |
| 0950 – 1010 hrs | Pregnancy & missed opportunitiesSybil Bravo (Philippines) | Pneumococcal Disease PreventionChiu Cheng Hsun (Taiwan) |
| 1010 – 1030 hrs | Travel VaccinesPornthep Chanthavanich (Thailand) | Respiratory Syncytial Virus (RSV)Lien Anh Ha Do (Australia) |
| Q&A | Q&A | |
| 1045 - 1145 hrs | Industry Symposia 1: AstraZeneca COVID-19 Vaccine Effectiveness: Myths vs RWE. Are Current Vaccines Optimal to Protect the Most Vulnerable? |
Industry Symposia 2: GSK Healthy Aging: Vaccines For Life |
| Chair: Bruce Mungall (Singapore) | Chair: H.T. Wickramasinghe (Sri Lanka) | |
 |
 |
|
|
Expert Global Review of COVID-19 Vaccine Effectiveness: Booster Doses Versus OmicronAnna Ong-Lim (Philippines) Third and Fourth Dose Effectiveness of COVID-19 Vaccines in Chiang Mai, ThailandSuwat Chariyalertsak (Thailand) The Unmet Need in High-Risk Groups Despite Vaccination: Leaving No- One BehindBarnaby Young (Singapore) |
Burden of VPDs in Adults & ElderlyGeorge Kassianos (United Kingdom) Advancement in Vaccinology: Increasing Vaccine Effectiveness in Adults & ElderlySelim Badur (Turkey) |
|
| 1145 - 1300 hrs | Symposium 3: COVID Vaccines |
Symposium 4: Communication and Advocacy |
| Chair: BJC Perera (Sri Lanka) | Chair: Dineshani Hettiarachchi (Sri Lanka) | |
|
COVID-19 Vaccinations for Children: Following the EvidenceBen Cowling (Hong Kong) "Special Population Groups” - Cancer Patients on Chemo, Transplant Patients, Dialysis Patients and Patients with Immune DeficiencyNeelika Malavige (Sri Lanka) Routine Childhood Immunizations During COVIDAnna Ong-Lim (Philippines) |
Latest Strategies to Communicate Vaccine SafetyPramod Jog (India) Communicating Impact of COVID on Childhood ImmunisationLois Privor (United States) Immunisation Agenda 2030: Geneva Learning FoundationCharlotte Mbuh (Switzerland) The Ethics of Challenge Studies to Fast Track Vaccine DevelopmentJulian Savulescu (United Kingdom) |
|
| Q&A | Q&A | |
| 1300 - 1330 hrs | Plenary Lecture 2 Chair: Tony Nelson (China) |
|
| Bats, Viruses and PandemicsLinfa Wang (Singapore) | ||
| 1330 - 1415 hrs | Panel 1: Pooled Procurement - Lessons Learned during COVID and Future OpportunitiesPartners: National Vaccine Institute, UNICEF |
Panel 2: Vaccine Confidence in the Asia Pacific RegionPartners: APAC Coalition |
Chair: Tony Nelson (China) |
Chair: Daniel Goh (Singapore) Lulu C. Bravo (Philippines) |
|
|
ASEAN Initiatives for Pooled ProcurementNakorn Premsri (Thailand) UNICEF's Pooled Procurement MechanismAndrew Jones (Denmark) |
Zulkifli Ismail (Malaysia) |
|
| 1415 - 1515 hrs | Industry Symposia 3: Takeda Takeda Dengue Symposium: Latest Update on Dengue |
Industry Symposia 4: Sanofi Sustaining Immunization for Children in the Current Era |
| Chair: Puneet Kalra (India) | Chair: Anna Ong-Lim (Philippines) | |
 |
 |
|
|
Current Status of Dengue in Sri Lanka and Asian CountriesNeelika Malavige (Sri Lanka) Clinical Managment of DengueA. LakKumar Fernando (Sri Lanka) Brief Overview of Takeda Dengue Vaccine (TAK -003) with 4.5 year data resultsVianney Tricou (Switzerland) |
Addressing the Challenges of Increasing Immunization Rates with Combination VaccinesFederico Martinon Torres (Spain) Global Polio Eradication Initiative: Role of wP Combination containing IPV vaccineMouloud Khris (Morocco) |
|
| 1515 hrs | End of Day 1 Programme | |
The Programme below is based on IST time (GMT +5.30)
| Timing (IST / GMT +5.30) |
DAY 2: 18 Sept 2022, Sunday | |
|---|---|---|
| Stream 1 | Stream 2 | |
| 0900 - 0930 hrs | Plenary Lecture 3 Chair: Zulkifli Ismail (Malaysia) |
|
| Priority Vaccines for Developing World (Malaria, HIV)Peter Hotez (United States of America) | ||
| 0930 - 1045 hrs | Symposium 5: Enteric VaccinesPartners: ROTA Council/ PATH/ IVI |
Symposium 6: Unfinished Business |
| Chair: Shaman Rajindrajith (Sri Lanka) | Chair: Jennifer Perera (Sri Lanka) | |
| 0930 – 0950 hrs | Cholera Vaccine LandscapeJulia Lynch (South Korea) | HPV Vaccine Updates: Evidence towards Use of Single DoseDaniel Chulwoo Rhee (United States of America) |
| 0950 – 1010 hrs | Typhoid Vaccines: Experience from Early IntroducersAziza Mwisongo (United States of America) | Dengue Vaccine UpdatesOoi Eng Eong (Singapore) |
| 1010 – 1030 hrs | Current Status Oral Rotavirus VaccinesCarl Kirkwood (United States of America) | PolioSomia Iqtadar (Pakistan) |
| 1030 – 1045 hrs | Q&A | Q&A |
| 1045 - 1145 hrs | Industry Symposia 5: MSD Challenges and Prospects of Pneumococcal Prevention in Adults Within Asia Pacific Chair: Rontgene Solante (Philippines) |
|
 | ||
| Key Considerations in Pneumococcal Prevention in Adult Population and Future ProspectsPaul Van Buynder (Australia) | ||
| Challenges and Prospects of Pneumococcal Prevention in Adults in the Asia Pacific RegionTerapong Tantawichien (Thailand) | ||
| 1145 - 1155 hrs | FREE PAPER SESSION A Chair: Dilini Nakkawita (Sri Lanka) |
FREE PAPER SESSION B Chair: A. H. Hazari (Sri Lanka) |
| Vaccines in Development: Immunogenicity and Safety of Hexavalent DTwP-IPV-HB-PRP~T Vaccine Compared With Licensed Pentavalent DTwP-HB-PRP~T Vaccine in Healthy Infants In Thailand: A Phase III Randomized StudyLeilani Sanchez (Philippines) | Disease-Specific Vaccines: Correlation Between Patient-reported and Clinician-assessed Symptoms and Case Definition to Capture Moderate- to-Severe RSV Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b StudyEsther Heijnen (United States of America) | |
| 1155 - 1205 hrs | Disease-Specific Vaccines: Effectiveness of COVID-19 vaccine booster doses against Omicron-related serious diseaseRontgene Solante (Philippines) | Monitoring and Surveillance: Effectiveness of heterologous 3rd and 4th dose COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and omicron predominance in Thailand.Suwat Chariyalertsak (Thailand) |
| 1205 - 1215 hrs | Vaccines in Development: Antibody Persistence After Primary Series With DTwP-IPV-HB-PRP~T Compared With Separate DTwP-HB-PRP~T and IPV Vaccines, and Booster Response to DTwP-IPV-HB-PRP~T in Healthy Toddlers in IndiaSomnath Mangarule (India) | Targeted Vaccination Strategies: Literature review on the knowledge, attitude and practice regarding herpes zoster and zoster vaccination in Asia-PacificJing Chen (Singapore) |
| 1215 - 1225 hrs | Disease-Specific Vaccines: IgG antibody response among recipients of the ChAdOx1 nCoV-19 Vaccine: A single center experience from Sri LankaDhanuka Dhanaratna (Sri Lanka) | Evidenced-based Introduction of New Vaccines: Capturing the value of vaccination within health technology assessment and health economics - Literature review and novel conceptual frameworkYu-Fan Ho (Singapore) |
| 1225 - 1235 hrs | Disease-Specific Vaccines: Regimen Selection and 1.5-year Immunogenicity Evaluation of Prophylactic Ad26.RSV.preF Vaccine Combinations: A Randomised, Double-Blind, Placebo-Controlled, Adaptive Design Phase 1/2a Study in Adults Aged ≥60 YearsArangassery Rosemary Bastian (United States of America) | Monitoring and Surveillance: Covid 19 Immunization Tracking in low resource setting using Opensource information systemsGumindu Kulatunga (Sri Lanka) |
| 1235 - 1245 hrs | Vaccines in Specific Settings: Evaluation of immunity against hepatitis B virus infection and factors associated with anti-HBs levels among vaccinated haemodialysis patients at two major Nephrology-Units in Sri LankaMohamed Asmir (Sri Lanka) | Targeted Vaccination Strategies: The epidemiology and cost of dengue disease in Sri Lanka: a systematic literature reviewJing Shen (Switzerland) |
| 1300 - 1330 hrs | Plenary Lecture 4Chair: Dhanushka Dasanayake (Sri Lanka) | |
| The Next Pandemic - Are We Prepared?Paul Anantharajah Tambyah (Singapore) | ||
| 1330 - 1415 hrs | Panel 3: Meet the Vaccine ExpertsPartners: Philippine Foundation for Vaccines, IPAP, APPA, Immunise for Life (Malaysia) Chair: Lulu C. Bravo (Philippines) |
|
| Rose Capeding (Philippines) Piprim (Indonesia) Zulkifli Ismail (Malaysia) Usa Thisyakorn (Thailand) |
||
| 1415 - 1445 hrs | Closing Plenary LectureChair: Kim Mulholland (Australia) | |
| Vaccines: What Does the Future Hold?Jerome Kim (South Korea) | ||
| 1445 - 1515 hrs | Prize Presentation IPAP & Organising Chair of ASVAC 2023 Speech Closing CeremonyLulu C. Bravo (Philippines) | |
Disclaimer: The Organising Committee may, in its discretion, amend any part of the programme without prior notice.